Arsine Poisoning
No Results
No Results
processing….
Arsine, the most toxic form of arsenic, is often produced from the reduction of inorganic arsenic salts with the use of acids and metal cofactors such as zinc. [1] Possible sources of occupational exposure are many, including microchip production in the semiconductor industry and other industries in which workers are involved in galvanizing, soldering, etching, and lead plating. Arsine may also be produced inadvertently by mixing arsenic-containing insecticides and acids.
Arsine has some properties that may make it useful as a chemical warfare (CW) agent [2] ; it is a colorless, odorless, nonirritating gas that is 2.5 times denser than air. At concentrations above 0.5 ppm, a garliclike odor may be noted; however, arsine is toxic at much lower concentrations.
Once in the body, arsenic is readily distributed, with peak serum levels occurring in approximately 60 minutes. Excretion of arsenic occurs mostly by the kidneys, with excretion in sweat, feces, and bile in small amounts. [3]
Although it has been investigated as a CW agent, no battlefield use of arsine has been documented. During and prior to World War II, the British studied this agent and rejected its use in the field. They concluded that arsine was more than 10 times less toxic than phosgene (CG) and was both difficult to manufacture and highly flammable. Although arsine was determined not to be useful as a battlefield CW agent, concern exists that it may be useful as a small-scale weapon of assassination or terror.
In contrast, several arsine-derived organoarsenic compounds have been developed and used as CW agents, including lewisite (beta-chlorovinyldichloroarsine), adamsite (diphenylaminearsine), Clark I (diphenylchlorarsine), and Clark II (diphenylcyanoarsine).
Inhaled arsine gas is distributed rapidly and causes massive red blood cell hemolysis that can potentially lead to global cellular hypoxia. The exact mechanisms leading to hemolysis have not been fully elucidated, but oxidative cell lysis has been suggested.
A study of mice exposed to moderate-to-high levels of arsine for 90 days revealed a significant decrease in hemoglobin and hematocrit along with an increase in mean corpuscular hemoglobins and mean corpuscular hemoglobin concentrations after 5 days of exposure. [4] Blood collected at 15 and 90 days showed a less severe anemia but a greater increase in mean corpuscular volumes and absolute reticulocyte count indicating a regenerative response. At 90 days, the concentration of methemoglobin was increased along with an increase in intracellular denatured proteins, or Heinz bodies. In addition, this particular study determined that arsine gas significantly depletes reduced intracellular glutathione resulting in greater oxidative damage to red blood cells.
Other mechanisms of hemolysis may include the inhibition of catalase and the formation of reactive oxidative species (ROS), such as hydrogen peroxide, within the cell. The damage induced by free radicals causes the denaturing of hemoglobin. This ultimately is believed to promote an abnormal association of hemoglobin with the erythrocyte membrane proteins that increase fragility of the erythrocyte membrane. Many researchers believe that hemolysis is a direct result of an arsenic dihydride intermediate and elemental arsenic produced from oxidized arsine. While there is disagreement of the reactive species involved and the mechanism of destruction, it is plausible that arsine causes cellular destruction by multiple mechanisms and the oxidative pathophysiology of arsine is well supported.
To further support an oxidative mechanism, human blood exposed to arsine pretreated with a sulfahydryl inhibitor N-ethylmaleimide (NEM) in vitro, resulted in less hemolysis. These results suggest that arsine may negatively interact with membrane sulfahydrl groups resulting in ion membrane changes that ultimately lead to hemolysis. [5]
Interestingly, the oxidative cytotoxicity potential of arsenic has been used as treatment for certain malignant cancers. In treating malignant melanoma, a widely known oxidant named menadione was used in combination with arsenic to increase reactive oxidative species (ROS) production and subsequent apoptosis in tumor cells. The two were found to work synergistically with a significantly higher level of apoptosis in the group treated with arsenic. [6] Similarly patients with acute promyelocytic leukemia (APL) were treated with transretinoic acid and arsenic trioxide. Compared to control, the group treated with the combination yielded a high complete remission rate of 93% and a significantly shorter time to enter complete remission. [7]
In due course, with massive hemolysis, renal failure due to tubular destruction is an important sequelae of arsine toxicity. [8] Although arsine may have direct effects on the renal system, most of the damage is believed to result indirectly from the breakdown of red blood cells and the increased load of hemoglobin. As in rhabdomyolysis, this destroys the tubular network leading to renal failure and is further complicated by renal hypoxia secondary to the decreased oxygen capacity of the blood.
Arsine has been reported to cause immediate death at 150-250 ppm. In addition to absolute concentration, the duration of exposure is another factor that determines toxicity. Exposure to 25-50 ppm for 30 minutes or 100 ppm for less than 30 minutes may also result in massive red blood cell hemolysis and ultimately death. Symptoms may be noticed with concentrations as low as 0.15 ppm, and delirium may be seen at 10 ppm.
Most of the reported deaths are believed to have been secondary to acute renal failure. Of arsine-induced renal failure cases, 100% were fatal prior to the advent of hemodialysis. More recent mortality rates for patients with acute arsine toxicity report death in approximately 25% or less of reported cases.
Sattar A, Xie S, Hafeez MA, Wang X, Hussain HI, Iqbal Z, et al. Metabolism and toxicity of arsenicals in mammals. Environ Toxicol Pharmacol. 2016 Dec. 48:214-224. [Medline].
Li C, Srivastava RK, Athar M. Biological and environmental hazards associated with exposure to chemical warfare agents: arsenicals. Ann N Y Acad Sci. 2016 Aug. 1378 (1):143-157. [Medline]. [Full Text].
Lee JY, Eom M, Yang JW, Han BG, Choi SO, Kim JS. Acute kidney injury by arsine poisoning: the ultrastructural pathology of the kidney. Ren Fail. 2013. 35(2):299-301. [Medline].
Blair PC, Thompson MB, Bechtold M, Wilson RE, Moorman MP, Fowler BA. Evidence for oxidative damage to red blood cells in mice induced by arsine gas. Toxicology. 1990 Jul. 63(1):25-34. [Medline].
Rael LT, Ayala-Fierro F, Carter DE. The effects of sulfur, thiol, and thiol inhibitor compounds on arsine-induced toxicity in the human erythrocyte membrane. Toxicol Sci. 2000 Jun. 55(2):468-77. [Medline].
Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C, Chaudhuri K. Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis. 2009 Jan. 14(1):108-23. [Medline].
Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, Xu YX, et al. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol. 2009. 121(1):1-8. [Medline].
Pullen-James S, Woods SE. Occupational arsine gas exposure. J Natl Med Assoc. 2006 Dec. 98(12):1998-2001. [Medline].
Centers for Disease Control and Prevention. Case Definition: Arsine or Stibine Poisoning. Emergency Preparedness and Response. Available at http://emergency.cdc.gov/agent/arsine/casedef.asp. April 4, 2018; Accessed: February 16, 2019.
Wilkinson SP, McHugh P, Horsley S, Tubbs H, Lewis M, Thould A, et al. Arsine toxicity aboard the Asiafreighter. Br Med J. 1975 Sep 6. 3(5983):559-63. [Medline].
Hsu LI, Hsieh FI, Wang YH, Lai TS, Wu MM, Chen CJ, et al. Arsenic Exposure From Drinking Water and the Incidence of CKD in Low to Moderate Exposed Areas of Taiwan: A 14-Year Prospective Study. Am J Kidney Dis. 2017 Dec. 70 (6):787-797. [Medline].
Centers for Disease Control and Prevention. Agency for Toxic Substances and Disease Registry. Medical Management Guidelines for Arsine. Available at https://www.atsdr.cdc.gov/MMG/MMG.asp?id=1199&tid=278. October 21, 2014; Accessed: February 16, 2019.
Hesdorffer CS, Milne FJ, Terblanche J, Meyers AM. Arsine gas poisoning: the importance of exchange transfusions in severe cases. Br J Ind Med. 1986 May. 43(5):353-5. [Medline].
Teitelbaum DT, Kier LC. Arsine poisoning. Report of five cases in the petroleum industry and a discussion of the indications for exchange transfusion and hemodialysis. Arch Environ Health. 1969 Jul. 19(1):133-43. [Medline].
Pullen-James S, Woods SE. Occupational arsine gas exposure. J Natl Med Assoc. 2006 Dec. 98(12):1998-2001. [Medline].
Danielson C, Houseworth J, Skipworth E, Smith D, McCarthy L, Nanagas K. Arsine toxicity treated with red blood cell and plasma exchanges. Transfusion. 2006 Sep. 46(9):1576-9. [Medline].
Song Y, Wang D, Li H, Hao F, Ma J, Xia Y. Severe acute arsine poisoning treated by plasma exchange. Clin Toxicol (Phila). 2007 Sep. 45(6):721-7. [Medline].
Bjørklund G, Mutter J, Aaseth J. Metal chelators and neurotoxicity: lead, mercury, and arsenic. Arch Toxicol. 2017 Dec. 91 (12):3787-3797. [Medline].
Kosnett MJ. The Role of Chelation in the Treatment of Arsenic and Mercury Poisoning. J Med Toxicol. 2013 Nov 1. [Medline].
Kermit D Huebner, MD, FACEP Research Director, Carl R Darnall Army Medical Center
Kermit D Huebner, MD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, Association of Military Surgeons of the US, Society for Academic Emergency Medicine, Society of United States Air Force Flight Surgeons
Disclosure: Nothing to disclose.
Ren M Kinoshita, DO Resident Physician, Department of Emergency Medicine, Carl R Darnall Army Medical Center
Ren M Kinoshita, DO is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Osteopathic Association
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Duane C Caneva, MD, MSc Senior Medical Advisor to Customs and Border Protection, Department of Homeland Security (DHS) Office of Health Affairs; Federal Co-Chair, Health, Medical, Responder Safety Subgroup, Interagency Board (IAB)
Disclosure: Nothing to disclose.
Fred Henretig, MD Director, Section of Clinical Toxicology, Professor, Medical Director, Delaware Valley Regional Poison Control Center, Departments of Emergency Medicine and Pediatrics, University of Pennsylvania School of Medicine, Children’s Hospital
Disclosure: Nothing to disclose.
Arsine Poisoning
Research & References of Arsine Poisoning|A&C Accounting And Tax Services
Source
0 Comments